Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,059 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Takeda Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

NCT00856284
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Metformin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
94
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

NCT01898884
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
VP 20629, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

NCT02038647
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Alisertib, Placebo, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

NCT02706626
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
brigatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 19, 2026, 10:44 PM EDT
Active, not recruiting No phase listed Observational

Post-Marketing Study of Prucalopride Safety In Pregnancy

NCT04869280
View directory record Official record
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 1 Interventional

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011
View directory record Official record
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

NCT00727857
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone and metformin, Pioglitazone, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
66
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Completed No phase listed Observational

Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling

NCT00677508
View directory record Official record
Conditions
Constipation, Fecal Incontinence
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

NCT00157040
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

NCT00456508
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

NCT01078376
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil (TAK-491)
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 3 Interventional

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Not applicable Interventional Results available

Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression

NCT04891224
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pathway Platform mobile app
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension

NCT00555880
View directory record Official record
Conditions
Hypotension, Orthostatic
Interventions
Midodrine hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Fort Wayne, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

NCT07205718
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAK-188
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 10:44 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT05020015
View directory record Official record
Conditions
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Interventions
TAK-007, Chemotherapy Agents
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 10:44 PM EDT
Completed Phase 1 Interventional

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCT03283917
View directory record Official record
Conditions
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Daratumumab, Dexamethasone, Ixazomib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 1 Interventional

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

NCT01541670
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 19, 2026, 10:44 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 19, 2026, 10:44 PM EDT